World Journal of Pharmaceutical and Life Sciences <u>WJPLS</u>

www.wjpls.org

SJIF Impact Factor: 5.088

A CROSS-SECTIONAL PROSPECTIVE STUDY TO ASSESS THE COMORBIDITIES IN CONGESTIVE CARDIAC FAILURE

Uthkarsha Vinesh*¹, Nikhil Kurian², Nivya P. S.², Vanendra Yadav S.², Nandan H. N.², Divya Shree N.³

¹Principal Investigator, Pharm D, Department of Pharmacy Practice, Bharathi College of Pharmacy, Bharathinagara, K. M. Doddi, Mandya, Karnataka, India – 571422.

²Pharm D, Department of Pharmacy Practice, Bharathi College of Pharmacy, Bharathinagara, K. M. Doddi, Mandya, Karnataka, India – 571422.

³Assistant Professor, Department of Pharmacy Practice, Bharathi College of Pharmacy, Bharathinagara, K. M. Doddi, Mandya, Karnataka, India – 571422.

*Corresponding Author: Uthkarsha Vinesh

Principal Investigator, Pharm D, Department of Pharmacy Practice, Bharathi College of Pharmacy, Bharathinagara, K. M. Doddi, Mandya, Karnataka, India – 571422.

Article Received on 17/06/2018

Article Revised on 08/07/2018

Article Accepted on 29/07/2018

ABSTRACT

Background: Congestive cardiac failure (CCF) is a complex clinical syndrome of multiple symptoms, functional impairments, and poor health-related quality of life (HRQoL).CCF patients are usually older and with a high number of comorbidities. Persisting symptoms and poor HRQoL after optimisation of CCF treatments suggest that comorbidities may be an important determinant of health and that non-cardiovascular comorbidities may be associated with CCF related symptoms. Method: This six month cross sectional descriptive study was conducted in 150 patients after obtaining approval from the Institutional Ethical Committee, MIMS, Mandya. The records of adults (>18 years) who are admitted with congestive cardiac failure to the ICU and MICU of Mandya Institute of Medical Science (MIMS) and Teaching Hospital, Mandya were studied and analysed using suitable statistical methods. Results: Our study found that there were more patients with 1-3 comorbidities and comorbidities present were ischaemic heart disease (48%), hypertension (44%), diabetes mellitus (20%), anaemia (16%), chronic obstructive pulmonary disease (16%), cardiomyopathy (12%), acute coronary syndrome (10%), angina (6%), myocardial infarction (6%), corpulmonale (6%), kidney failure (6%), cerebrovascular accident (4%), liver abnormalities (4%), hypernatremia (4%), asthma (4%) and respiratory failure (4%), Eisenmenger syndrome (2%), dyslipidaemia (2%), pleural effusion (2%), hypoglycaemia (2%), hypoproteinaemia (2%), acute gastritis (2%) and neck of femur (2%). Our study indicates that there were more male patients who had comorbidities with CCF compared to female patients. Conclusion: There were more patients with 1-3 comorbidities and the most common comorbidities were ischaemic heart disease, hypertension, diabetes mellitus, anaemia, chronic obstructive pulmonary disease, cardiomyopathy and acute coronary syndrome. Our study indicates that more male patients had comorbidities than female patients.

KEYWORDS: Congestive cardiac failure, comorbidity, ischaemic heart disease, hypertension.

INTRODUCTION

Congestive cardiac failure (CCF) is a complex clinical syndrome of multiple symptoms, functional impairments and poor health-related quality of life (HRQoL). With modern therapies, CCF patients are now living longer but with a potentially higher symptom burden,^[11] that can be worse compared to people with other chronic diseases including cancer.^[2] Inadequate symptom control and poor HRQoL are significant drivers of hospitalisations, readmissions, and death in CCF.^[3,4] CCF patients are usually older, with a high number of comorbidities, and a third of patients report that other medical conditions dominate their health experience,^[5] yet guideline-driven symptom management in CCF focuses on cardiovascular

status.^[6] Persisting symptoms and poor HRQoL after optimisation of CCF treatments,^[7] suggest that comorbidities may be an important determinant of health and that non-cardiovascular comorbidities may be associated with CCF related symptoms.^[8] However, the evidence is inconsistent, with some CCF studies showing associations between comorbidities and HRQoL.^[9-11] and others showing no such associations.^[12,13] Whilst comorbidities are consistent predictors of morbidity and mortality in HF.^[14] their interrelationships with symptoms, functional limitations, and overall health have not been explored.

METHODOLOGY

Study population

The study was conducted in 150 patients who have congestive cardiac failure and were admitted in ICU and MICU of Mandya Institute of Medical Science (MIMS) and Teaching Hospital, Mandya which is a 650 bedded hospital.

Study method

This was a six months cross sectional descriptive study in which the data were collected from the patient's case records. The study was approved by Institutional Ethical Committee, MIMS, Mandya. The records of adults (>18 years) who are admitted with congestive cardiac failure to ICU and MICU of MIMS were chosen for the study and the records of patients whose diagnosis was not certain; pregnant or lactating females and patients less than 18 years were excluded from the study.

Statistical analysis: Descriptive analysis was used to analyse the data.MS Excel and MS Word were used for analysing the data. Qualitative variables were expressed as mean standard deviation and percentage.

RESULTS

Among the 150 patients of congestive cardiac failure studied, 87 (58%) were males and 63 (42%) were females for which the mean age was found to be 65.08 ± 14.11 years.

Table 1: Distribution based on gender of patients.

Gender	No. of Patients	Percentage of Patients (%)
Male	87	58
Female	63	42



Figure 1: Gender wise categorization of patients.

The total population when classified into 3 categories of age group, 6 (4%) patients fell into class A, 45 (30%) belonged to class B and 99 (66%) were in class C.

Class	Age Group (Years)	No. of Patients	Percentage of Patients (%)
Α	18-40	6	4
В	40-65	45	30
С	≥65	99	66



Figure 2: Age wise categorization of patients.

Patient Distribution Based on Comorbidities

Based on the number of comorbidities seen, the study population was classified into 5 categories which included 3 patients (2%) in category I, 54 patients (36%) in category II, 30 patients (20%) in category III, 45 patients (30%) in category IV and 18 patients (12%) in category V.

 Table 3: Distribution of patients based on the number of comorbidities.

Category	No. of comorbidities in patients	No. of patients	Percentage of patients (%)
Ι	0	3	2
II	1	54	36
III	2	30	20
IV	3	45	30
V	>3	18	12



Figure 3: Distribution of patients based or comorbidities

Distribution of Various Comorbidities In Patients

Among the population studied the major comorbidities were ischaemic heart disease (48%), followed by hypertension (44%), diabetes mellitus (20%), anaemia (16%) and chronic obstructive pulmonary disease (16%), cardiomyopathy (12%), acute coronary syndrome (10%) followed by angina, myocardial infarction, corpulmonale and kidney failure which were seen in 6% of the patients, cerebrovascular accident, liver abnormalities, hypernatremia, asthma and respiratory failure which accounted for 4% of the patients and Eisenmenger syndrome, dyslipidaemia, pleural effusion, hypoglycaemia, hypoproteinaemia, acute gastritis and neck of femur which accounted for 2% of them.



Figure 4: Distribution of various comorbidities in patients (CCF – congestive cardiac failure, COPD – chronic obstructive pulmonary disorder, DM – diabetes mellitus, IHD – ischaemic heart disease, HTN – hypertension).

Table 4: Distribution of various comorbidities in patients.

Comorbidity	No. of patients	Percentage of Patients (%)
Ischaemic heart disease	72	48
Hypertension	66	44
Diabetes mellitus	30	20
Anaemia	24	16
Chronic obstructive pulmonary disease	24	16
Cardiomyopathy	18	12
Acute coronary syndrome	15	10
Angina	9	6
Myocardial infarction	9	6
Corpulmonale	9	6
Kidney failure	9	6
Cerebrovascular accident	6	4
Liver abnormalities	6	4
Hypernatremia	6	4
Asthma	6	4
Respiratory failure	6	4
Eisenmenger syndrome	3	2
Dyslipidaemia	3	2
Pleural effusion	3	2
Hypoglycaemia	3	2
Hypoproteinaemia	3	2
Acute gastritis	3	2
Neck of femur	3	2

Gender Wise Categorization of Comorbidities

When the comorbidities were dealt in detail with its occurrence in male and female patients, the result in

table 5 was obtained and it was observed that more male patients developed comorbidities than female patients.



Figure 5: Classification of comorbidities in males and females.

Table 5:	Classification	of	comorbidities i	in	males	and	females.
I abie et	Classification	U	comor brancies		marco		remaies

Comorbidity	No. of male patients	No. of female patients
Ischaemic heart disease	33 (45.8%)	39 (54.2%)
Hypertension	20 (30.3%)	46 (69.7%)
Diabetes mellitus	15 (50.0%)	15 (50.0%)
Anaemia	11 (45.8%)	13 (54.2%)
Chronic obstructive pulmonary disease	22 (91.7%)	2 (8.3%)
Cardiomyopathy	10 (55.6%)	8 (44.4%)
Acute coronary syndrome	7 (46.7%)	8 (53.3%)
Angina	6 (66.7%)	3 (33.3%)
Myocardial infarction	8 (88.9%)	1 (11.1%)
Corpulmonale	7 (77.8%)	2 (22.2%)
Kidney failure	6 (66.7%)	3 (33.3%)
Cerebrovascular accident	4 (66.7%)	2 (33.3%)
Liver abnormalities	5 (83.3%)	1 (16.7%)
Hypernatremia	3 (50.0%)	3 (50.0%)
Asthma	5 (83.3%)	1 (16.7%)
Respiratory failure	4 (66.7%)	2 (33.3%)
Eisenmenger syndrome	3 (100.0%)	0 (0.0%)
Dyslipidaemia	1 (33.3%)	2 (66.7%)
Pleural effusion	2 (66.7%)	1 (33.3%)
Hypoglycaemia	1 (33.3%)	2 (33.3%)
Hypoproteinaemia	0 (0.0%)	3 (100.0%)
Acute gastritis	3 (100.0%)	0 (0.0%)
Neck of femur	2 (66.7%)	1 (33.3%)

DISCUSSION

The records of 150 patients with congestive cardiac failure based on the inclusion criteria in the General Medicine Department of the MIMS were analysed and the mean age was found to be 65.08 ± 14.11 years. Majority of them were male patients ie. 87 numbers (58%) while the remaining 63 (42%) were female patients.

The population was classified into three classes based on the patients age as class A, class B, class C which represented the age groups 18-40 years, 40-65 years and \geq 65 years respectively. 6 (4%) patients fell into class A, 45 (30%) into class B and 99 (66%) were found to fall into class C.

Further, the study population was categorized based on the number of comorbidities seen into category I, II, III, IV and V which denoted patients with no comorbidity, patients with 1 comorbidity, 2 comorbidities, 3 comorbidities and >3 comorbidities respectively. Majority of the patients belonged to category II [54 patients (36%)] followed by category IV [45 patients (30%)], category III [30 patients (20%)] and category V [18 patients (12%)]. There were very less patients [18 patients (12%)] who belonged to category I.

Among the population studied the major comorbidity was ischaemic heart disease (48%), followed by hypertension (44%), diabetes mellitus (20%). The other comorbidities were anaemia (16%) and chronic obstructive pulmonary disease (16%), cardiomyopathy (12%), acute coronary syndrome (10%) followed by angina, myocardial infarction, corpulmonale and kidney failure which were seen in 6% of the patients, cerebrovascular accident, liver abnormalities, hypernatremia, asthma and respiratory failure which accounted for 4% of the patients and Eisenmenger pleural dyslipidaemia, syndrome, effusion, hypoglycaemia, hypoproteinaemia, acute gastritis and neck of femur which accounted for 2% of them.

Our findings shows agreement to the results of the study conducted by Claire A. Lawson et al. in terms of the major comorbidities [ischaemic heart disease (54%), hypertension (52%), diabetes mellitus (24%)] except atrial fibrillation which accounted for 48% of their study population.^[15]

When the comorbidities were dealt in detail with its occurrence in male and female patients, it was observed that more male patients developed comorbidities than female patients.

CONCLUSION

Our findings concludes that congestive cardiac failure is mostly seen in males and the age group in which it is mostly found is ≥ 65 years and it is least in the age group of 18-40 years. There were more patients with 1-3 comorbidities and the most common comorbidities were ischaemic heart disease, hypertension, diabetes mellitus, anaemia, chronic obstructive pulmonary disease, cardiomyopathy and acute coronary syndrome. Our study indicates that more male patients had comorbidities than female patients.

ACKNOWLEDGEMENT

I express my sincere gratitude to my family and my best friend Nandan H.N. for their constant support and motivation throughout the project.

BIBLIOGRAPHY

- 1. Alpert CM, Smith MA, Hummel SL, Hummel EK. Symptom burden in heart failure: assessment, impact on outcomes, and management. Heart Fail Rev., 2017; 22(1): 25-39.
- 2. Comin-Colet J, Anguita M, Formiga F, Almenar L, Crespo-Leiro MG, Manzano L, et al. Health-related quality of life of patients with chronic systolic heart failure in Spain: results of the VIDA-IC study. Rev Esp Cardiol, 2016; 69(3): 256-71.
- Lupon J, Gastelurrutia P, De Antonio M, Gonzalez B, Cano L, Cabanes R, et al. Quality of life monitoring in ambulatory heart failure patients: Temporal changes and prognostic value. Eur J Heart Fail, 2013; 15(1): 103-9.
- 4. Iqbal J, Francis L, Reid J, Murray S, Denvir M. Quality of life in patients with chronic heart failure and their carers: a 3-year follow-up study assessing hospitalization and mortality. Eur J Heart Fail, 2010; 12(9): 1002-8.
- Joyce E, Chung C, Badloe S, Odutayo K, Desai A, Givertz MM, et al. Variable contribution of heart failure to quality of life in ambulatory heart failure with reduced, better, or preserved ejection fraction. JACC Heart Fail, 2016; 4(3): 184-93.
- 6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J., 2016; 37(27): 2129-200.
- 7. Lewis EF. Assessing the impact of heart failure therapeutics on quality of life and functional capacity. Curr Treat Options Cardiovasc Med., 2013; 15(4): 425-36.
- Rushton CA, Kadam UT. Impact of noncardiovascular disease comorbidity on cardiovascular disease symptom severity: a population-based study. Int J Cardiol, 2014; 175(1): 154±61.
- Hamo CE, Heitner JF, Pfeffer MA, Kim HY, Kenwood CT, Assmann SF, et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circ Heart Fail, 2015; 8(2): 268-77.
- 10. Fujita B, Lauten A, Goebel B, Franz M, Fritzenwanger M, Ferrari M, et al. Impact of

diabetes mellitus on quality of life in patients with congestive heart failure.

- 11. Uchmanowicz I, Gobbens RJ. The relationship between frailty, anxiety and depression, and healthrelated quality of life in elderly patients with heart failure. Clin Interv Aging, 2015; 10: 1595-600.
- 12. Bohme S, Renneberg B. Predicting self-rated health in diabetes and chronic heart failureĐa multiple mediation model. Front Public Health, 2015; 3: 266.
- 13. Nesbitt T, Doctorvaladan S, Southard JA, Singh S, Fekete A, Marie K, et al. Correlates of quality of life in rural patients with heart failure. Circ Heart Fail, 2014; 7(6): 882-7.
- 14. Van Deursen VM, Urso R, Laroche C, Damman K, DahlstroÈm U, Tavazzi L, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail, 2014; 16(1): 103-11.
- 15. Claire A. Lawson, Ivonne Solis-Trapala, Ulf Dahlstrom, Mamas Mamas, Tiny Jaarsma, Umesh T. Kadam, Anna Stromberg. Comorbidity health pathways in heart failure patients: A sequences-ofregressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. PLOS Medicine, 2018; 27: 1-18.